Mendus – equity proposition

Mendus (OMX: IMMU) is a clinical-stage immuno-oncology company based in Sweden and the Netherlands. It is focused on developing active immunotherapies to improve long-term survival in cancers, including blood-borne tumours, that are underserved by current immunotherapies, such as immune checkpoint inhibitors. The company’s lead clinical programme, vididencel, is an off-the-shelf cellular immunotherapy that is being developed as a maintenance therapy for acute myeloid leukaemia (AML).

There are five key reasons why Mendus may be considered an attractive investment opportunity.

1. The clinical data for vididencel in AML to date has been very encouraging.
2. Vididencel is an off-the-shelf therapy.
3. A key differentiating characteristic of Mendus is its manufacturing capabilities.
4. The company has multiple upcoming inflection points.
5. Mendus has a broad offering, mitigating its exposure to binary risk events.

If you would like to find out more about Mendus, please see our website.